The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data.

Liem, Esmee Iml; Oddens, J R; Vernooij, Rwm; Li, R; Kamat, A M; Dinney, C P; Mengual, L; Alcaraz, A; Izquierdo, L; Savic, S; Thalmann, George; Bubendorf, L; Sylvester, R J; de Reijke, T M (2020). The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data. The journal of urology, 203(2), pp. 283-291. Wolters Kluwer Health 10.1097/JU.0000000000000566

[img] Text
JU.0000000000000566.pdf - Accepted Version
Restricted to registered users only until 25 September 2020.
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

PURPOSE The objective of this study was to assess the value of fluorescence in situ hybridization (FISH) for predicting early recurrence in intermediate-, and high-risk NMIBC patients treated with BCG. MATERIALS AND METHODS A systematic review was conducted using MEDLINE, Embase and the Cochrane library. Individual patient data (IPD) from prospective observational studies evaluating FISH in patients treated with BCG were included. A two-stage IPD meta-analysis was carried out to assess the value of FISH for predicting tumor recurrence after BCG induction therapy. RESULTS From four studies IPD were obtained of 422 patients, and 408 patients included in final analysis with a median follow-up of 18.8 months. The hazard ratio for recurrence when FISH was positive was pre-BCG (t0) 1.20 (95% CI: 0.81-1.79), at six weeks (t1) 2.23 (95% CI: 1.31-3.62), at three months (t2) 3.70 (95% CI: 2.34 - 5.83), and at six months (t3) 23.44 (95% CI: 5.26-104.49). CONCLUSION A positive FISH test post-BCG correlates with a higher risk for a tumor recurrence. FISH could aid urologists in risk stratification and counseling of patients. Based on both HR and its narrowest CI, the preferred timing for FISH is three months following TURBT. This is also in time for patients who fail to respond to induction therapy to enter clinical trials, or to change treatment strategy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Thalmann, George

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1527-3792

Publisher:

Wolters Kluwer Health

Language:

English

Submitter:

Jeannine Wiemann

Date Deposited:

05 Nov 2019 16:54

Last Modified:

10 Jan 2020 01:31

Publisher DOI:

10.1097/JU.0000000000000566

PubMed ID:

31549936

Uncontrolled Keywords:

Urinary bladder neoplasms fluorescence in situ hybridization meta-analysis mycobacterium bovis recurrence

BORIS DOI:

10.7892/boris.134481

URI:

https://boris.unibe.ch/id/eprint/134481

Actions (login required)

Edit item Edit item
Provide Feedback